Acute GVHD Suppression Using Co-Stimulatory Blockade with Abatacept to Expand Non-Malignant Transplant: Preliminary Results from the Multicenter Ascent Trial

Key Points

• Acute GVHD suppression was observed in non-malignant transplant recipients using abatacept.
• The study found a significant reduction in GVHD incidence within the first 100 days post-transplant.
• Observational analysis across multiple centers evaluated the effects of co-stimulatory blockade on GVHD.
• The findings highlight the potential of abatacept in non-malignant transplant settings for better immune response.